petesherl, the Calimmune HIV treatment is for humans as was the previous HIV trial at City of Hope but both of these trials relied on removing cells from the patients, modifying them and re-introducing them to the patient. TT-034, on the other hand, will be injected directly into the patients and as such is seen as the first "in human" ddRNAi treatment.
According to the information provided by the company at the time of the CR they have sufficient funds to move NSCLC into a Pl/ll trial.
The other pipeline programs are basically on maintenance as we progress the two main ones. Additional funds will be required to make any significant progress in these other programs. This capital may be forthcoming if one of the main programs gets a buy-in from big pharma.
- Forums
- ASX - By Stock
- BLT
- Ann: Annual Report to shareholders
Ann: Annual Report to shareholders , page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online